{"chunk_id": "_Drugs-in-Pregnancy-and-Lactation--Improved-Benefit-Risk-Information_-January-22--2015-Issue__chunk_16", "source": "_Drugs-in-Pregnancy-and-Lactation--Improved-Benefit-Risk-Information_-January-22--2015-Issue", "text": "pending with the agency on June 30, 20 15 must comply within \nfour years of the effective date, or at the time of approval, whichever is later.  Previously approved prescription products that were \napproved on or after June 30, 2001 have a phased-in implementation schedule from 3-5 years, as outlined in Section IV of the PLLR.  \nSeveral manufacturers have already incorporated labeling changes in anticipation of the publication of the final PLLR, so man y \nproducts on the market already have lab"}